BACKGROUND: Obesity is associated with a wide variety of metabolic disorders that impose significant burdens on patients and society. The "browning" phenomenon in white adipose tissue (WAT) has emerged as a promising therapeutic strategy to combat metabolic disturbances. However, though the anti-diabetic drug dapagliflozin (DAPA) is thought to promote "browning," the specific mechanism of this was previously unclear. METHODS: In this study, C57BL/6 J male mice were used to establish an obesity model by high-fat diet feeding, and 3T3-L1 cells were used to induce mature adipocytes and to explore the role and mechanism of DAPA in "browning" through a combination of in vitro and in vivo experiments. RESULTS: The results show that DAPA promotes WAT "browning" and improves metabolic disorders. Furthermore, we discovered that DAPA activated "browning" through the fibroblast growth factor receptors 1-liver kinase B1-adenosine monophosphate-activated protein kinase signaling pathway. CONCLUSION: These findings provide a rational basis for the use of DAPA in treating obesity by promoting the browning of white adipose tissue.
Adipose Tissue, White , Benzhydryl Compounds , Glucosides , Protein Serine-Threonine Kinases , Receptor, Fibroblast Growth Factor, Type 1 , Signal Transduction , Animals , Male , Mice , 3T3-L1 Cells , Adipocytes/metabolism , Adipocytes/drug effects , Adipose Tissue, Brown/drug effects , Adipose Tissue, Brown/metabolism , Adipose Tissue, White/metabolism , Adipose Tissue, White/drug effects , AMP-Activated Protein Kinases/metabolism , Benzhydryl Compounds/pharmacology , Diet, High-Fat , Glucosides/pharmacology , Mice, Inbred C57BL , Obesity/metabolism , Obesity/drug therapy , Protein Serine-Threonine Kinases/metabolism , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Receptor, Fibroblast Growth Factor, Type 1/genetics , Signal Transduction/drug effects
